Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
| Vertex Pharmaceuticals Inc (NASDAQ: VRTX) | Delayed: 524.52 +9.87 (1.92%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $514.65 | 52 Week High | $134.71 | |||
| Open | $512.79 | 52 Week Low | $73.31 | |||
| Day High | $528.57 | P/E | N/A | |||
| Day Low | $510.48 | EPS | $-1.98 | |||
| Volume | 1,448,630 | |||||
